Chimeric Antigen Receptor (CAR) T-Cell Therapy Market in 8MM – Market Insights, Market Assessment and Market Forecast (2023-2030)

Chimeric Antigen Receptor (CAR) T-Cell Therapy – Report Overview

Pacific Business Consulting’s “Chimeric Antigen Receptor (CAR) T-Cell Therapy Market in 8MM – Market Insights, Market Assessment and Market Forecast (2023-2030)” report offers a comprehensive exploration of Chimeric Antigen Receptor (CAR) T-Cell Therapy, encompassing historical and projected market size data, along with market trends, market drivers, market barriers and unmet medical needs in the Eight Major Markets (8MM) of the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and China.

In 2022, the global market for CAR T-cell Therapy, valued at US$2.2 billion, is anticipated to reach US$9.2 billion by 2030, reflecting a robust Compound Annual Growth Rate (CAGR) of over 20% during the forecast period from 2023 to 2030.

According to the analysis by Pacific Business Consulting, the Chimeric Antigen Receptor (CAR) T-Cell Therapy market is expected to experience substantial growth at a considerable Compound Annual Growth Rate (CAGR) throughout the forecast period. The total market size for Chimeric Antigen Receptor (CAR) T-Cell Therapy will encompass both the potential upcoming therapies and current treatment regimens within the market. Significant advancements in cancer immunotherapy have resulted in the approval of currently available CAR-T cell therapies.

CAR-T cell therapy represents a highly promising approach for treating cancer patients. This form of immunotherapy involves collecting immune cells, modifying them in a laboratory, and empowering them to easily recognize and eliminate cancer cells. Once infused into a patient, these modified cells proliferate and persist in the body as “living drugs.”

The foundation of CAR-T cell therapy lies in T-cells, the essential components of our immune system responsible for directing immune responses and eliminating pathogen-infected cells. In CAR-T cell therapy, patient blood is drawn, and T-cells are isolated. In the laboratory, a disarmed virus is used to genetically engineer these T-cells to express chimeric antigen receptors (CARs) on their surface. Upon infusion into the patient, these CARs enable T-cells to recognize and bind to antigens on cancer cells, resulting in their destruction.

Key players in this sector include Gilead Sciences, Inc., Celgene Corporation, Abintus Bio, Inc., Adicet Bio, Alaunos Therapeutics, Inc., Aleta BioTherapeutics, AffyImmune Therapeutics, Inc., Arcellx, Anixa Biosciences, Inc., Aurora BioPharma, and Aavocyte, Inc.

Scope of Report

The report addresses critical subjects such as strategic competitor evaluation, market characterization, unmet needs, and the consequences of these elements for the Chimeric Antigen Receptor (CAR) T-Cell Therapy market. It also delves into the analysis of present and prospective market competition within the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market.

Furthermore, the report offers an insightful examination of the primary industry drivers, constraints, and challenges. Each trend undergoes independent research to furnish qualitative analysis regarding its implications.

Reasons to Buy

• Develop your business strategies by gaining insights into the trends that shape and drive the Chimeric Antigen Receptor (CAR) T-Cell Therapy market across the 8MM (Eight Major Markets).
• Increase revenue by comprehending key trends, innovative products and technologies, market segments, and companies poised to influence the future of the 8MM Chimeric Antigen Receptor (CAR) T-Cell Therapy market.
• Craft effective sales and marketing strategies by thoroughly understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially robust product portfolios and devise strategic counter-strategies to gain a competitive advantage.
• Optimize your sales and marketing efforts by pinpointing market categories and segments that offer the greatest opportunities for consolidations, investments, and strategic partnerships.

Please note that detailed pipeline analysis can be provided along with the standard scope to assist you in developing and designing your in-licensing and out-licensing strategies. This includes a review of pipeline products and technologies, along with identifying companies with the most robust pipeline.

1. Executive Summary: Chimeric Antigen Receptor (CAR) T-Cell Therapy
   • Global Market Outlook; Chimeric Antigen Receptor (CAR) T-Cell Therapy
2. Competitive Intelligence Analysis; Chimeric Antigen Receptor (CAR) T-Cell Therapy
3. Therapeutic Sector SWOT
4. Technology Roadmap Analysis
5. Market Background
   • Drivers
   • Restraints
   • Opportunity
   • Key Market Trends
   • Key Unmet Needs
6. Chimeric Antigen Receptor (CAR) T-Cell Therapy: Key Marketed Products Profile – Major Approved Products
   • Product Profile
   • Regulatory Milestones
   • Safety and Efficacy
   • Clinical Development
7. Chimeric Antigen Receptor (CAR) T-Cell Therapy: Promising Pipeline Candidates – Major Products in Late Stage of Development
   • Product Description
   • Safety and Efficacy
   • Research and Development
8. Regulatory Landscape
9. Chimeric Antigen Receptor (CAR) T-Cell Therapy: Eight Major Market (8MM) – Market Analysis
   • Historical Market Analysis (US$ million), 2020-2022
   • Current and Future Market Projections (US$ million), 2023-2030
10. S. Chimeric Antigen Receptor (CAR) T-Cell Therapy – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
11. K. Chimeric Antigen Receptor (CAR) T-Cell Therapy – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
12. Germany Chimeric Antigen Receptor (CAR) T-Cell Therapy – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
13. France Chimeric Antigen Receptor (CAR) T-Cell Therapy – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
14. Italy Chimeric Antigen Receptor (CAR) T-Cell Therapy – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
15. Spain Chimeric Antigen Receptor (CAR) T-Cell Therapy – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
16. Japan Chimeric Antigen Receptor (CAR) T-Cell Therapy – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
17. China Chimeric Antigen Receptor (CAR) T-Cell Therapy – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
18. Competitive Landscape
    • Company Overview
    • Product Portfolio
    • Key Financials
    • Sales Footprint

Note – All Major Company Profiles (Count up to 20) will be covered in the report

19. Assumptions and Acronyms Used
20. Research Methodology
    • Secondary Research
    • Primary Research
    • Data Triangulation
21. Geographic Scope
    • The U.S., The U.K., Germany, France, Italy, Spain, Japan, and China

Copyrights and Disclaimer